Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 1/20 | 0.36 |
| ▸ | LDHA | P00338 | 1/20 | 0.32 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5401604 | 0.82 | ECE1 (0.31) | ECE1ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL3907990 | 0.80 | ALDH1A1 (0.34) | ALDH1A1POLBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL1561959 | 0.78 | LDHA (0.35) | ECE1LDHASRRSMN1; SMN2 | |
| SCHEMBL5396143 | 0.77 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL25076167 | 0.74 | KDM4E (0.46) | ALDH1A1POLBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL12036660 | 0.74 | LDHA (0.50) | ECE1LDHASRRALDH1A1SMN1; SMN2 | |
| SCHEMBL4425505 | 0.71 | POLB (0.36) | ALDH1A1POLBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL4436509 | 0.71 | POLB (0.36) | ALDH1A1POLBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL4436504 | 0.71 | POLB (0.36) | ALDH1A1POLBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL4433155 | 0.69 | TSHR (0.32) | ECE1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1711470-B1 | MALONAMIDE DERIVATIVES BLOCKING THE ACTIVTIY OF GAMMA-SECRETASE | HOFFMANN LA ROCHE (CH) | 2009-04-15 | — | — | EP | disclosed |
| US-7160875-B2 | Malonamide derivatives | HOFFMANN-LA RACHE INC. (US) | 2007-01-09 | — | — | US | disclosed |
| EP-1711470-A1 | MALONAMIDE DERIVATIVES BLOCKING THE ACTIVTIY OF GAMMA-SECRETASE | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005023772-A1 | MALONAMIDE DERIVATIVES BLOCKING THE ACTIVITY OF GAMA-SECRETASE | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-17 | — | — | WO | disclosed |
| US-20050054633-A1 | secretase inhibitors; therapy for Alzheimer's disease | HOFFMANN-LA ROCHE INC. | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054633-A1 | secretase inhibitors; therapy for Alzheimer's disease | BACE1, BACE2, APP | ECE1 73/4885LDHA 2834/4885SRR 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.